Most Read Articles
Natalia Reoutova, 3 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).

MRI, post-MRI biopsy drive decision making in newly diagnosed favourable-risk prostate cancer

16 Apr 2019

Decision making in men with newly diagnosed favourable-risk prostate cancer is driven by magnetic resonance imaging (MRI) and post-MRI biopsy, according to a study, noting that post-MRI biopsy is a stronger driver of decision making than MRI alone.

“This was demonstrated by the >90 percent of men with reassuring post-MRI biopsies who elected active surveillance regardless of MRI results,” the authors said.

A total of 1,461 men with favourable-risk prostate cancer were included. Of these, 1,223 (84 percent) did not undergo MRI, 157 (11 percent) underwent MRI alone, and 81 (6 percent) underwent MRI and post-MRI biopsy.

There were more men with reassuring findings than those with nonreassuring or MRI findings who elected active surveillance (74 percent vs 35 percent and 42 percent, respectively) among patients who underwent MRI alone.

Furthermore, men with reassuring post-MRI biopsy had the highest rate of active surveillance regardless of whether MRI was reassuring or nonreassuring (93 percent and 96 percent, respectively).

The authors reviewed the records of men with newly diagnosed favourable risk prostate cancer in the Michigan Urological Surgery Improvement Collaborative. These men were classified into three groups following diagnostic biopsy: group 1, no MRI; group 2, MRI only; group 3, MRI/post-MRI biopsy.

MRI results were deemed reassuring (Prostate Imaging Reporting and Data System [PI-RADS] 3) or nonreassuring (PI-RADS 4) for purposes of counselling and shared decision making.

Additionally, if the diagnostic biopsy was grade group (GG) 1, post-MRI biopsy results were considered nonreassuring should there be any amount of GG 2. If the diagnostic biopsy was GG 2, post-MRI biopsy results were deemed nonreassuring if more than three cores were GG 2, or there was >50-percent GG2 in any individual core or any volume of GG 3.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 3 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).